Gates Foundation
Announces Grant to Eliminate Epidemic Meningitis
Bill & Melinda Gates Foundation
DOCUMENT
May 31, 2001
Posted to the web May 31, 2001
Washington
The Bill & Melinda
Gates Foundation announced today a global health grant of $70 million
in support of a partnership between Seattle-based Program for Appropriate
Technology in Health (PATH) and the World Health Organization (WHO) to
eliminate meningitis epidemics in sub-Saharan Africa. The newly created
Meningitis Vaccine Project is a ten-year partnership effort to develop
and introduce a serogroup A meningococcal conjugate vaccine in Africa.
This vaccine is expected
to provide immunity in infants, elicit longer duration of protection and
interrupt transmission for prevention of epidemics. Development and introduction
of this conjugate vaccine entails the establishment of a partnership with
the private sector and many other groups such as the U.S. Centers for
Disease Control and Prevention as the leading technical partner.
Between 1988 and 1997,
704,000 cases of meningitis and 100,000 deaths were reported in the so-called
"African meningitis belt," which stretches from Ethiopia in
East Africa to The Gambia in the west. The largest recorded epidemic,
with more than 200,000 cases and 20,000 deaths reported, occurred in 1996.
These reports typically substantially underestimate the actual burden
of the disease. During epidemics, routine reporting systems break down,
many patients die before reaching a health center, and the cause of death
goes unrecorded.
"We are pleased
that PATH and WHO seized a tremendous opportunity to build on existing
science to develop a new vaccine that will help save hundreds of thousands
of lives," said Dr. Gordon Perkin, Director, Global Health Program
at the Bill & Melinda Gates Foundation. "This strategic and cooperative
effort could mean the end of meningitis epidemics in Africa in our lifetime."
"This is a disease
that, during epidemics, fills hospitals, creates significant social disruption,
strains limited resources, and kills large numbers of people, mostly children,
in a short period of time," said Yasuhiro Suzuki, executive director,
health technologies and pharmaceuticals at WHO. "Finally, through
this partnership, we have the necessary resources not just to prevent
this disease in a few, but to put an end to these devastating epidemics
all together."
Epidemic meningitis
attacks a broad age range, with young people at particular risk. Infants
less than a year old are most at risk. Infection is characterized by high
fever, vomiting, and confusion, which can progress over several hours
to death. Despite antibiotic therapy, at least one in 10 with the disease
will die, and another 10 percent are left with neurologic disorders and
the loss of the use of their limbs through paralysis. Untreated, up to
50 percent of cases result in death.
"Traditionally,
market competition drives vaccine creation," said Dr. Chris Elias,
president of PATH. "However, in these very poor countries, there
isn't a market and subsequently there is little incentive for the private
sector to make the investment needed to develop such a vaccine. This grant
will provide the incentive that has been missing and may ultimately become
a model for other vaccines or drugs tailor-made for the poorest countries."
Over the next ten
years the Meningitis Vaccine Project will involve many partners, both
private and public, working to:
* Develop a meningococcal
conjugate vaccine * Create a pathway for the licensure of the vaccine
which will be used largely in Africa * Assure production in sufficient
volume to meet projected needs * Monitor throughout to assure the effectiveness
and safety of the intervention * Finance the procurement of the vaccine
through existing or new global programs * Introduce the vaccine through
mass and routine immunization programs in synergy with other public health
programs such as measles control initiatives
The Bill & Melinda
Gates Foundation is dedicated to improving people's lives by sharing advances
in health and learning with the global community. Led by Bill Gates' father,
William H. Gates, Sr., and Patty Stonesifer, the Seattle- based foundation
has an asset base of $21 billion. For complete information, visit www.gatesfoundation.org
<http://www.gatesfoundation.org.
Contact: Annemarie
Hou, Bill & Melinda Gates Foundation. Phone: 206.619.4456. E-mail:
annemarie@gatesfoundation.org
Evan Simpson, Program
for Appropriate Technology in Health (PATH). Phone: 206.285.3500. E-mail:
esimpson@path.org
Mahenau Agha, Vaccines
and Biological World Health Organization (WHO). Phone: 41.22.791.2232.
E-mail: agham@who.int
Marinela do Carmo,
APCO Africa. Phone : 27.11.480.8584. E-mail: mdocarmo@apco-africa.com
Copyright © 2001
Bill & Melinda Gates Foundation.
--------------------------------------------------------------------------------
Source: allAfrica.com.
Back
to top
Home
About Us Health
News Health Topics Country
Profiles Links
All contents copyright © 2000, 2001 MEDILINKS.ORG. All rights
reserved.
|